Tirzepatide vs Semaglutide in Las Vegas:
How Providers Actually Decide
Choosing between tirzepatide and semaglutide comes down to your goals, medical history, budget, and how your body responds. In trials of the brand-name medications, both produced significant weight loss and tirzepatide produced more on average; semaglutide is the established, lower-cost starting point. At Body Balance Medical in Summerlin, we walk Las Vegas patients through this decision with an individualized medical evaluation, not trends or marketing claims.
Body Balance Medical’s website is LegitScript-certified. LegitScript certification is not an endorsement or sponsorship of Body Balance Medical, and it is not a measure of quality of care. Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness or quality.
The Core Difference: One Receptor or Two
The fundamental difference between these two medications is how many hormone receptors each one targets.
Semaglutide is a GLP-1 receptor agonist. It mimics GLP-1, the hormone that regulates appetite and helps control blood sugar by slowing digestion and promoting fullness. This single-target approach has years of real-world data behind it for both weight management and diabetes care.
Tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP component is thought to affect how the body processes fat and energy.
Both slow gastric emptying, reduce appetite, and require medical supervision for safe and effective results. Which one fits you depends on individual factors, not average trial numbers.
What the Head-to-Head Trial Actually Found
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, is the most direct comparison available: adults with obesity, without type 2 diabetes, tirzepatide against semaglutide.
| Outcome at 72 Weeks | Tirzepatide | Semaglutide |
|---|---|---|
| Average body weight reduction | 20.2% | 13.7% |
| Average absolute weight loss | ~50 lbs | ~33 lbs |
| Waist circumference reduction | 18.4 cm | 13.0 cm |
| Patients reaching ≥25% weight loss | 31.6% | 16.1% |
| Discontinuation rate | Slightly lower | Slightly higher |
Source: Aronne LJ et al. SURMOUNT-5 Trial. N Engl J Med. 2025;393(1):26–36. Trial averages under study conditions using FDA-approved formulations, not a prediction of individual results.
Two things worth pulling out of that table. First, the discontinuation rate was slightly lower with tirzepatide, which suggests tolerability at effective doses is comparable despite the stronger efficacy. Second, and less discussed: semaglutide's 13.7% is itself a clinically significant result. It is not a consolation prize.
Semaglutide also carries well-documented cardiovascular evidence. In the SELECT trial, brand-name semaglutide showed roughly a 20% reduction in major cardiovascular events for patients with obesity (compounded semaglutide was not studied), a dimension of value beyond weight loss that matters for some patients more than the larger weight number.
Side Effects: More Similar Than Different
Both medications produce primarily gastrointestinal side effects (nausea, vomiting, diarrhea, constipation, occasional abdominal discomfort), concentrated during dose escalation and typically easing as the body adjusts. Gradual titration under supervision is the main tool for managing them, and it works for both.
Both carry a Boxed Warning for possible increased risk of thyroid tumors, including medullary thyroid carcinoma, based on animal studies. Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 are not candidates for either medication. A history of gallbladder disease, kidney disease, pancreatitis, or obstructive sleep apnea should be discussed with your provider before starting either.
At Body Balance Medical, provider oversight during dose escalation is built into both programs. Side effects that come up during titration get managed at your check-ins.
Cost: What Each Program Runs
Both are a real monthly investment, and for a lot of patients cost is the deciding factor rather than the trial data. Here is what each program costs at our Summerlin clinic.
Medication, weekly in-office injections, dose titration, and ongoing provider check-ins. See the program →
Same structure, with weekly in-office injections of a dual GIP/GLP-1 medication. Compounded Tirzepatide in Las Vegas →
Both are flat-rate and cash-pay. No per-visit fees, no separate management charges, no insurance required. Plans have a 4-month minimum and need 30 days' written notice to cancel. Compounded medications are generally not covered by insurance, which is why we price this way rather than sending you into a prior-authorization process with an uncertain outcome. HSA and FSA funds are generally accepted, and financing is available through Cherry and CareCredit.
The honest way to think about the $100 monthly difference: for patients who achieve substantially greater weight loss on tirzepatide, the cost per pound lost can favor the more expensive option. For patients who respond well to semaglutide, it doesn't. Nobody can tell you which group you're in before you start. That is the argument for supervised care with real check-ins.
How the Programs Actually Run
Both medications are once-weekly subcutaneous injections in the abdomen, thigh, or upper arm. Both require structured oversight to work properly. On our in-office plans, your weekly injections are given at our Summerlin clinic.
Semaglutide starts at 0.25mg weekly with gradual escalation based on your tolerance and response, with provider check-ins built in throughout. Tirzepatide follows the same structure starting at 2.5mg. Because tirzepatide has a dual mechanism and higher maximum doses, we monitor the escalation phase more closely to balance results against side effects.
Weight loss programs don't require lab work to begin. Your provider reviews your health history, current medications, and risk factors, and will tell you if something calls for testing.
How We Decide Which One Fits You
Seven factors go into the recommendation at your Medical Weight Loss Candidacy Evaluation:
Larger goals? Tirzepatide produced more weight loss on average in trials of the brand-name medications. Looking for a lower monthly cost? Semaglutide is $100 less a month.
Patients with cardiovascular concerns may favor semaglutide's more robust cardiovascular evidence base. Patients with type 2 diabetes need their diabetes care coordinated with any GLP-1 plan.
Patients who have plateaued on semaglutide or another GLP-1 are often strong candidates for tirzepatide. Your history informs the starting point.
Semaglutide at $299/month is the more accessible entry point. Tirzepatide is $399/month. Adherence over time matters more than the starting dose, so an honest budget conversation belongs at the front.
Some patients handle gastrointestinal effects more easily than others. Your history with GI sensitivity shapes both the choice and the titration pace.
Insulin sensitivity, diabetic retinopathy history, gallbladder disease, kidney function, and thyroid history all factor into which medication is appropriate and safe for you specifically.
Some patients want the longer track record and lower cost. Others want the most effective option regardless of price. Both are legitimate starting points.
Which One Should You Start With?
Longer Track Record.
Lower Entry Point.
- You want the medication with the longer real-world track record
- You're starting your weight loss journey and want a balanced approach
- A lower monthly investment matters for long-term adherence
- You have cardiovascular concerns that align with semaglutide's evidence base
Dual Mechanism.
Higher Trial Averages.
- You want the option with the higher average weight loss in trials of the brand-name medications
- You've plateaued on semaglutide or another GLP-1
- Your goals call for more weight loss
Many patients start on semaglutide and move to tirzepatide if they plateau or want to accelerate. The programs are built to work as a progression, and switching is a normal clinical decision rather than a failure. Your provider guides that based on how you actually respond.
Getting Started in Las Vegas
Body Balance Medical is at 7975 W Sahara Ave #101 in Summerlin, minutes from the 215, serving patients across Las Vegas. Your Medical Weight Loss Candidacy Evaluation covers your medical history, your goals, and a straight answer on whether semaglutide, tirzepatide, or a different approach fits your situation.
We handle dose escalation, monitor for side effects, and adjust as you respond. A balanced diet and regular activity meaningfully improve results with either medication; our GLP-1 diet guide covers the practical nutrition side, particularly protein targets for preserving lean mass.
Common Questions
In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss (20.2% versus 13.7% over 72 weeks), with slightly lower discontinuation rates, suggesting comparable tolerability.
Compounded versions were not part of that trial. That said, semaglutide's results are clinically significant in their own right, and it remains the appropriate choice for many patients based on goals, budget, and medical history.
At Body Balance Medical, Compounded Semaglutide is $299/month and Compounded Tirzepatide is $399/month. Both include weekly in-office injections, provider oversight, dose titration, and check-ins, with no separate fees. Plans have a 4-month minimum and need 30 days' written notice to cancel.
Yes, and it's common. Many patients start on semaglutide and transition if they plateau or want to accelerate results. Your provider manages the transition with attention to timing and dosing.
Starting on semaglutide is a clinically reasonable approach: it's an established medication and the cost difference genuinely matters for staying on treatment long enough to see results.
Broadly yes: primarily gastrointestinal effects like nausea, diarrhea, and constipation during dose escalation. In SURMOUNT-5, discontinuation rates were slightly lower with tirzepatide.
Both carry a Boxed Warning regarding thyroid tumor risk based on animal studies. Gradual titration under medical supervision is the main tool for minimizing side effects with either medication.
Both molecules were first approved, as brand-name products, for type 2 diabetes. In clinical trials of the brand-name medications, tirzepatide lowered HbA1c more than semaglutide.
If you have type 2 diabetes, your provider will coordinate any GLP-1 plan with the clinician who manages your diabetes.
Body Balance Medical is at 7975 W Sahara Ave #101 in Summerlin, minutes from the 215. Both programs are prescribed and supervised by our nurse practitioner, Teresa Hernandez, MSN FNP-BC.
Apply for a Medical Weight Loss Candidacy Evaluation and we'll review your history, walk through both options, and tell you which one we'd actually recommend for your situation.
It depends on your medical history, goals, budget, and clinical picture, assessed during a provider evaluation, not decided by a comparison article. This page exists to help you arrive at that conversation informed, not to make the decision for you.
Find Out Which Option
Fits Your Situation
Body Balance Medical offers Medical Weight Loss Candidacy Evaluations for patients across Las Vegas and Summerlin. We'll review your history, walk you through both options, and give you a straight answer.
Apply for Your EvaluationResults vary. Semaglutide and tirzepatide are prescription medications. Body Balance Medical prescribes compounded versions prepared by licensed compounding pharmacies. Compounded medications are not FDA-approved and are prescribed only after an individual clinical evaluation. Pricing is subject to change. This article is for informational purposes and does not constitute medical advice. All treatment decisions are made in consultation with a licensed medical provider. Body Balance Medical serves patients in Las Vegas and Summerlin, Nevada.